KAIMRC’s head of strategy and business development, Abdelali Al Haoudi, explained that launching this trial is a cornerstone for the kingdom’s clinical development.

The search for a vaccine that would curb the threat of Middle East respiratory syndrome (MERS) and stop the virus in its tracks has been central to KAIMRC’s clinical research efforts.